An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
FeNO
benralizumab
biological treatment
dupilumab
mepolizumab
omalizumab
reslizumab
severe asthma
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
11
2019
revised:
15
03
2020
accepted:
16
03
2020
pubmed:
15
7
2020
medline:
5
2
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
Asthma is a heterogeneous disease with regard to the inflammatory pathways activated. In recent years, biologic drugs (monoclonal antibodies) directed towards specific components of type 2 inflammation have been approved for the treatment of severe asthma. Phenotyping of patients with severe asthma and evaluation of biomarkers have been recommended to help identify patients who are candidates for treatment with biologics and to monitor treatment responses. Fractional exhaled Nitric Oxide (FeNO) is a biomarker of type 2 inflammation in asthma, signaling activation of Interleukin (IL)-4/IL-13 pathway. FeNO could be useful to assess treatment response or identify candidates for a specific drug that acts on type 2 inflammation mechanisms linked to Nitric Oxide (NO) production, such as the IL-4/IL-13 pathway or upstream processes. The value of FeNO as a biomarker predictive of responses to the biologics available for treating severe asthma is discussed based on the published studies at the moment of the review.
Identifiants
pubmed: 32660394
pii: CMC-EPUB-108140
doi: 10.2174/0929867327666200713184659
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Antibodies, Monoclonal
0
Biomarkers
0
Interleukin-13
0
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7159-7167Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.